Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 11, 2024

Keywords

ClinConnect Summary

The LIQPLAT study is looking at how blood tests can help doctors monitor cancer in patients with advanced solid tumors. Specifically, researchers want to see if measuring a substance called ctDNA (which is DNA from cancer cells found in the blood) during regular treatment can provide valuable information about a patient's condition. They will compare the experiences and health outcomes of patients who have this blood test with those who do not.

To participate in this study, patients must be at least 18 years old and have a confirmed diagnosis of a solid tumor that cannot be surgically removed or is advanced and inoperable. They should not have received any treatment for their cancer yet and must need medical treatment as decided by their doctor. Participants can expect to have blood drawn as part of their routine care, and the study aims to find out if this approach is practical and beneficial for managing their cancer. If you are interested in learning more or think you may qualify, please talk to your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned OR solid malignant tumors that are locally advanced and inoperable OR solid tumors that are metastatic
• • No prior treatment for advanced/metastatic disease
• • Indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician
• • Patient age 18 years and older
• • General research consent of the University Hospital Basel
• Exclusion Criteria:
• • ● Patients with primary brain tumors